Clinical Trial

A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Airway Mucus Hypersecretion

Enrolling by Invitation Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 20, 2025 (before its estimated April 23, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a phase II, randomised, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of HSK31858 in patients with airway mucus hypersecretion in chronic airway inflammatory diseases
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-06.
Trial Details
NCT Number NCT06820749
Lead Sponsor Haisco Pharmaceutical Group Co., Ltd.
Conditions Asthma Bronchiale, Bronchiectasis, Chronic Obstructive Pulmonary Disease (COPD)
Enrollment 309 participants
Start Date 2024-12-10
Primary Completion 2026-04-23 (estimated)
Study Completion 2026-06-22 (estimated)
Updated on ClinicalTrials.gov 2025-02-20